<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01697410</url>
  </required_header>
  <id_info>
    <org_study_id>2012A080204018;200705</org_study_id>
    <nct_id>NCT01697410</nct_id>
  </id_info>
  <brief_title>Continuos Terlipressin Infusion in Septic Shock</brief_title>
  <official_title>A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Province, Department of  Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Bengbu Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hainan People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiâ€™an Jiaotong University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhuhai  People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of terlipressin for treating septic
      shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Septic shock is the most common cause of death in intensive care units and has a mortality
      rate of 40 to 60%.Vasopressin is commonly used as an adjunct to catecholamines to support
      blood pressure in refractory septic shock.Recently small sample clinical study suggest that
      Terlipressin,a vasopressin analogues, was effective in reversing sepsis-induced arterial
      hypotension and in reducing norepinephrine requirements.But its effect on mortality is
      unknown.Invesgators hypothesized that Terlipressin as compared with norepinephrine would
      decrease mortality among patients with septic shock.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>28-days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>SOFA score was measured on day0-7 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>days alive and free of vasopressor</measure>
    <time_frame>during the first 28 days after the start of the infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Days of vasopressor  were recorded after the start of the infusion in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days after the start of the  infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure</description>
    <arm_group_label>terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure</description>
    <arm_group_label>norepinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock was defined by the presence of two or more diagnostic criteria for the
             systemic inflammatory responsesyndrome, proven or suspected infection, and
             hypotension (exclusion of hypertention other than sepsis)

        Exclusion Criteria:

          -  organ transplantation;

          -  pregancy or breast-feeding;

          -  malignancy or other irreversible disease or condition for which has a poor prognosis;

          -  acute coronary syndrome;

          -  chronic heart failure(NYHA III or IV)/cardiogenic shock;

          -  acute mesenteric ischemia;

          -  greater than 48 hours had elapsed since the patient met entry criteria;

          -  estimation of incomplite treament due to financial problem;

          -  use of terlipressin for blood pressure support before entry;

          -  Raynaud's phenomenon, systemic sclerosis or vasospastic diathesis;

          -  registration of other clinical trial which will affect the outcome of the current
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guan XiangDong, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>first affiliated hospital  SunYetSen university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>liu ZiMeng, M.D</last_name>
    <role>Study Director</role>
    <affiliation>first affiliated hospital ,SunYetSen university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Si Xiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>first affiliated hospital ,SunYetSen university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen Juan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>first affiliated hospital ,SunYetSen university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guan Xiangdong, M.D.</last_name>
    <phone>862087755766-8456</phone>
    <email>carlg@163.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu Zimeng, M.D.</last_name>
    <phone>862087755766-8454</phone>
    <email>sumslzm@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guan Xiangdong, M.D.</last_name>
      <phone>862087555766-8456</phone>
      <email>carlg@163.net</email>
    </contact>
    <investigator>
      <last_name>Guan Xiangdon, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>September 27, 2012</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Guan XiangDong</investigator_full_name>
    <investigator_title>director of surgical intensive care unit</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
